ENVB
Enveric Biosciences, Inc. NASDAQ Listed May 4, 2015$1.48
+1.37%
vs $1.46
Mkt Cap $495.4K
52w Low $1.27
2.2% of range
52w High $10.80
50d MA $1.47
200d MA $2.31
P/E (TTM)
-0.1x
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.0x
ROE
-210.0%
P/FCF
-0.1x
RSI (14)
50.00
ATR (14)
$0.09
Beta
0.33
50d MA
$1.47
200d MA
$2.31
Avg Volume
73.7K
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
4851 Tamiami Trail North · Naples, FL 34103 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | AMC | — | -0.76 | — | 1.54 | -3.2% | -3.9% | -8.8% | -3.0% | +6.1% | +2.9% | — |
| May 15, 2026 | AMC | — | -1.08 | — | 2.25 | -2.2% | -4.4% | -1.9% | +4.3% | +0.9% | -0.5% | — |
| Mar 27, 2026 | AMC | -55.80 | 0.85 | +101.5% | 1.88 | -3.2% | -4.8% | +8.4% | +10.3% | -5.1% | -2.0% | — |
| Nov 14, 2025 | AMC | -63.00 | -10.81 | +82.8% | 5.28 | -0.6% | -5.9% | +14.1% | +3.0% | +0.2% | +2.1% | — |
| Aug 14, 2025 | AMC | -63.00 | -11.64 | +81.5% | 13.32 | +0.0% | -0.9% | +8.2% | -4.2% | +1.8% | +0.0% | — |
| Aug 11, 2025 | AMC | -63.00 | -11.64 | +81.5% | 13.08 | +0.0% | -1.8% | +3.7% | +0.0% | -0.9% | +8.2% | — |
| May 14, 2025 | AMC | -6.00 | -1.22 | +79.7% | 15.72 | +0.0% | -3.8% | +3.2% | +4.6% | -0.7% | -8.1% | — |
| May 13, 2025 | AMC | -72.00 | -14.64 | +79.7% | 17.16 | +1.4% | -8.4% | -3.8% | +3.2% | +4.6% | -0.7% | — |
| Mar 31, 2025 | AMC | -3.45 | -57.96 | -1580.0% | 16.68 | -2.2% | -5.8% | +3.8% | -5.9% | -5.5% | -5.0% | — |
| Nov 14, 2024 | AMC | -0.52 | -43.20 | -8207.7% | 71.52 | -4.0% | -8.1% | -3.3% | +0.6% | -1.5% | -3.8% | — |
| Aug 12, 2024 | AMC | -0.55 | -45.00 | -8081.8% | 94.44 | +6.7% | +1.4% | -7.9% | -1.4% | +1.7% | +2.6% | — |
| May 15, 2024 | AMC | -0.77 | -109.79 | -9999.0% | 141.84 | +0.0% | +14.2% | -6.7% | -2.2% | +0.8% | +0.2% | — |
| May 14, 2024 | AMC | -9.15 | -9.15 | +0.0% | 147.72 | -0.6% | -4.0% | +14.2% | -6.7% | -2.2% | +0.8% | — |
| Mar 26, 2024 | AMC | -1.55 | -262.77 | -9999.0% | 190.80 | -1.9% | -3.8% | -2.0% | -11.0% | +28.1% | -11.4% | — |
| Mar 25, 2024 | AMC | -23.24 | -21.89 | +5.8% | 189.00 | -1.0% | +1.0% | -3.8% | -2.0% | -11.0% | +28.1% | — |
| Nov 13, 2023 | AMC | -347.37 | -233.98 | +32.6% | 273.60 | -2.6% | -1.3% | -5.0% | +1.0% | +4.2% | -2.7% | — |
| Aug 14, 2023 | AMC | -0.65 | -45.58 | -6912.3% | 482.40 | -2.2% | -11.2% | -5.5% | -2.2% | -2.3% | +7.4% | — |
| Jun 8, 2023 | AMC | — | -6.76 | — | 732.60 | -0.2% | -6.6% | -2.4% | +4.6% | -6.2% | +6.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.20 | $24.24 | -3.8% | -8.6% | -5.2% | -5.5% | -1.2% | -5.3% |
| Jun 1 | Alliance Global Partners | Maintains | Buy → Buy | — | $1779.36 | $1890.00 | +6.2% | +6.2% | +2.6% | -1.1% | -2.7% | +4.9% |
| Mar 8 | Aegis Capital | Downgrade | Buy → Hold | — | $2251.80 | $2250.00 | -0.1% | +5.9% | +4.3% | +3.0% | -2.3% | -6.5% |
| Jul 8 | Aegis Capital | Maintains | Buy → Buy | — | $18720.00 | $18630.00 | -0.5% | +10.1% | +1.7% | -0.9% | -3.9% | -4.1% |
| Jun 28 | Maxim Group | Maintains | Buy → Buy | — | $19530.00 | $21330.00 | +9.2% | +19.8% | -5.8% | -2.9% | -3.4% | -4.8% |
No insider trades available.
8-K · 2.02
!! High
Enveric Biosciences, Inc. -- 8-K 2.02: Earnings Results
Aug 14
8-K · 7.01
! Medium
Enveric Biosciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 9
8-K · 8.01
!! High
Enveric Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 9
8-K · 2.02
!! High
Enveric Biosciences, Inc. -- 8-K 2.02: Earnings Results
May 15
8-K · 1.01
! Medium
Enveric Biosciences, Inc. -- 8-K 1.01: Equity Issuance
Enveric Biosciences issued Series I and J warrants with $2.00 exercise prices, offering investors future upside if the stock appreciates above that level before expiration dates ranging from 18 months to five years.
Apr 20
8-K
Unknown — 8-K Filing
Enveric's expanded patent portfolio for non-hallucinogenic therapeutic molecules strengthens competitive moats and potential market exclusivity, making it an attractive play for investors seeking psychedelic medicine exposure without regulatory hallucinogen complications.
Mar 27
8-K · 8.01
!! High
Enveric Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Enveric Biosciences has sold $1.85 million in common stock through its at-the-market offering agreement with Wainwright, providing capital for operations and development.
Feb 6
Institutional (13F) — Top 9
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Renaissance Technologies Llc | 32,058 | $44K | New | Jun 2026 |
| 2 | Citadel Advisors Llc | 27,930 | $39K | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 14,912 | $21K | New | Jun 2026 |
| 4 | Ubs Group Ag | 3,612 | $7K | Added | Mar 2026 |
| 5 | Sbi Securities Co., Ltd. | 2,676 | $4K | New | Jun 2026 |
| 6 | Blackrock, Inc. | 51 | $70 | New | Jun 2026 |
| 7 | Virtu Financial Llc | 10,690 | $15 | New | Jun 2026 |
| 8 | Wells Fargo & Company/mn | 1 | $2 | New | Mar 2026 |
| 9 | Danske Bank A/s | 1 | $1 | — | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF | 35,417 | $49K | Jun 2026 |
| 2 | Fidelity Extended Market Index Fund | 6,968 | $16K | Feb 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 911 | $2K | Feb 2026 |
Valuation
Market Cap
$495K
Enterprise Value
-$4.2M
P/E (TTM)
-0.09x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.12x
P/S
—
P/FCF
-0.06x
EV/EBITDA
—
Shares Out
335K
Financials (TTM)
Revenue
$0
Net Income
-$8.7M
EBITDA
-$8.6M
Free Cash Flow
-$8.1M
Op Cash Flow
-$8.1M
EPS Basic
$-36.24
EPS Diluted
$-16.46
EPS Forward
$-315.00
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$5.1M
Total Liab.
$918K
Total Equity
$4.2M
Cash
$4.7M
LT Debt
$0
Book Value/Sh
$12.48
Debt/Equity
0.00x
Current Ratio
5.38
Quick Ratio
5.38
Returns & Growth
ROE
-210.0%
ROA
-172.1%
ROIC
-210.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+84.1%
Price Returns
2W
-8.2%
1M
+1.4%
3M
+0.7%
6M
-28.1%
12M
-84.3%
Technicals
52W High
$10.80
52W Low
$1.27
50d MA
$1.47
200d MA
$2.31
RSI (14)
50.00
ATR (14)
$0.09
Beta
0.33
Avg Volume
74K
Dividends
Div Rate
$10.04
Div Yield
251.5%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 7:17am
· Source: financialmodelingprep.com